Blog Tag
7 articles tagged with Biotech Regulation. The newest post is from Mar 6, 2026.
A companion diagnostic is a test used to identify patients who are most likely to benefit from a specific therapy or to avoid patients who may face higher risk. In biotech, companion diagnostics matter because they make precision medicine practical. They help match the right treatment to the right patient.
An exclusivity period is a time during which a drug is protected from certain forms of competition after approval. In biotech, exclusivity matters because it gives the company time to commercialize the product without immediate copycat competition. That protection is one of the key reasons innovative drugs can generate meaningful revenue after launch.
A post-marketing study is a study a company conducts after a drug has been approved and marketed. The purpose may be to confirm benefit, collect longer-term safety data, study a new population, or satisfy an FDA requirement tied to an approval pathway such as accelerated approval. In biotech, post-marketing studies matter because approval is often not the end of the regulatory story.
Accelerated approval is an FDA pathway that allows certain drugs for serious conditions to be approved based on a surrogate endpoint or another intermediate clinical measure that is reasonably likely to predict benefit. In biotech, the pathway matters because it can bring promising therapies to patients sooner when waiting for traditional long-term outcomes would be impractical.
Priority review is an FDA review classification that shortens the target review timeline for certain applications. In biotech, the term matters because it usually means the agency believes the application, if approved, could provide significant improvement in safety or effectiveness for treating serious conditions. The result is a faster review process and a closer focus on the filing.
Fast track designation is an FDA status intended to speed the development and review of drugs that treat serious conditions and fill an unmet medical need. In biotech, the designation matters because it can help promising therapies move more efficiently through the regulatory process.
Breakthrough therapy designation is an FDA status for drugs that show preliminary clinical evidence suggesting the therapy may offer substantial improvement over existing options for one or more serious or life-threatening conditions. In biotech, the designation matters because it can accelerate development and increase the level of interaction between the company and the FDA.
